Keyword

ALK mutations

Description: ALK mutations are genetic alterations in the anaplastic lymphoma kinase gene, studied in cancer biology and targeted treatment.

Primary topic: Lung Cancer Treatments and Mutations (41%)

Wikidata ID: wiki/Q28445138

OpenAlex ID: keywords/alk-mutations

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

2019 · Narjust Duma, Rafael Santana-Davila, et al. · Mayo Clinic Proceedings · 2,197

Neuroblastoma

2016 · Katherine K. Matthay, John M. Maris, et al. · Nature Reviews Disease Primers · 1,484

Non-small-cell lung cancer

2015 · Cesare Gridelli, Antonio Rossi, et al. · Nature Reviews Disease Primers · 1,121

Oncogenic mutations of ALK kinase in neuroblastoma

2008 · Yuyan Chen, Junko Takita, et al. · Nature · 917

Activating mutations in ALK provide a therapeutic target in neuroblastoma

2008 · Rani E. George, Takaomi Sanda, et al. · Nature · 897

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

2008 · Isabelle Janoueix-Lerosey, Delphine Lequin, et al. · Nature · 895

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

2014 · Luc Friboulet, Nanxin Li, et al. · Cancer Discovery · 842

PDF

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

2013 · Bengt Hallberg, Ruth H. Palmer · Nature reviews. Cancer · 645

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

2015 · Helen Y. Zou, Luc Friboulet, et al. · Cancer Cell · 471

PDF

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

2016 · Wei-Sheng Huang, Shuangying Liu, et al. · Journal of Medicinal Chemistry · 412

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

2014 · Scott C. Bresler, Daniel A. Weiser, et al. · Cancer Cell · 389

PDF

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

2010 · Yihua Sun, Yan Ren, et al. · Journal of Clinical Oncology · 335

Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition

2012 · Robert Roskoski · Pharmacological Research · 303

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

2014 · Carlo Gambacorti Passerini, Francesca Farina, et al. · JNCI Journal of the National Cancer Institute · 279

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

2010 · Sara De Brouwer, Katleen De Preter, et al. · Clinical Cancer Research · 279

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

2011 · Scott C. Bresler, Andrew C. Wood, et al. · Science Translational Medicine · 237

Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways

2011 · Neerav Shukla, Nabahet Ameur, et al. · Clinical Cancer Research · 232

Retinoblastoma and Neuroblastoma Predisposition and Surveillance

2017 · Junne Kamihara, Franck Bourdeaut, et al. · Clinical Cancer Research · 228

Emergence of New ALK Mutations at Relapse of Neuroblastoma

2014 · Gudrun Schleiermacher, Niloufar Javanmardi, et al. · Journal of Clinical Oncology · 215

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

2013 · Jim Sang, Jaime Acquaviva, et al. · Cancer Discovery · 208

Neuroblastoma

2018 · Akira Nakagawara, Yuanyuan Li, et al. · Japanese Journal of Clinical Oncology · 201

ALK: a tyrosine kinase target for cancer therapy

2017 · Vijaykumar R. Holla, Yasir Y. Elamin, et al. · Molecular Case Studies · 192

PDF

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

2011 · Johannes M. Heuckmann, Michael Hölzel, et al. · Clinical Cancer Research · 191

PDF

Targeting ALK in neuroblastoma—preclinical and clinical advancements

2012 · Erica L. Carpenter, Yael P. Mossé · Nature Reviews Clinical Oncology · 178

Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients

2009 · Lorena Passoni, Luca Longo, et al. · Cancer Research · 173

Works count: 1,478

Citation count: 26,700